Characterization of dysphagia and longitudinal changes in swallowing function in adults with Niemann‑Pick disease type C treated with miglustat

Miglustat is currently the only approved disease-specific treatment shown to be effective in stabilizing neurological symptoms. Miglustat has previously been reported to halt or improve early dysphagia and cognitive symptoms. Here we examine the characteristics of dysphagia, the relationship between dysphagia and the presence of cognitive impairment, and longitudinal changes in swallowing function during miglustat treatment in adult-and-adolescent-onset NPC.

Redenlab awarded new clinical trial with Top 10 Pharma company

Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab are providing audio capture and analytics for a Phase 1b clinical trial. Conducted in sites across the USA, the study will investigate the long-term efficacy of a treatment designed to ameliorate the impact of this rare and debilitating disease.

Sensitivity of acoustic measures extends to recreational users of cannabis

Subtle differences in speech timing, vocal effort, and voice quality were found between cannabis and control groups. After controlling for lifetime alcohol and tobacco use, the cannabis group presented with longer and more variable pauses across tasks, and vocal effort was different compared to controls. Vocal effort and intensity also appeared to change in line with duration of abstinence from cannabis use – that is, they appeared get better the longer they stayed away from the drug. The differences observed between users and controls may reflect longer term changes to the underlying neural control of speech.